BPG is committed to discovery and dissemination of knowledge
Featured Articles
2/19/2019 9:59:03 AM | Browse: 687 | Download: 1640
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 42249
Country Italy
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Study
Article Title Redox, immune and genetic biomarker’s system for personalized treatments in colorectal cancer
Manuscript Source Invited Manuscript
All Author List Anna Maria Berghella, Anna Aureli, Angelica Canossi, Tiziana Del Beato, Alessia Colanardi and Patrizia Pellegrini
Funding Agency and Grant Number
Corresponding Author Anna Maria Berghella, PhD, Research Scientist, Consiglio Nazionale delle Ricerche (CNR), Istituto di Farmacologia Traslazionale (IFT), via G Carducci, 32, L'Aquila 67100, AQ, Italy. annamaria.berghella@cnr.it
Key Words Aging and cancer biomarker; Cancer personalized treatments; Oxidation and immune biomarkers; Trx1/CD30 target; KIRs and FcR polymorphisms; Th cytokines; Aging and disease; Cancer-related mechanisms
Core Tip Identifying biomarkers able of point out the risk of development of degenerative processes linked to aging and colorectal cancer (CRC) onset, could improve clinical strategies. The aim was to establish if Trx1 and CD30 as dual target, combined with cytokines and polymorphisms of KIRs, FcRIIa-131H/R and FcRIIIa-158V/F, was more effective. Serum measures of Trx1/CD30, RTrx1, multiple cytokine levels and polymorphisms of KIR and FcγRIIa were used to estimate the effect of disease, age and gender to describe the variants in the biology of the redox immune system. Through these procedures, the redox immune fingerprint of health, ageing and cancer states was determined.
Publish Date 2019-02-15 09:46
Citation Berghella AM, Aureli A, Canossi A, Del Beato T, Colanardi A, Pellegrini P. Redox, immune and genetic biomarker’s system for personalized treatments in colorectal cancer. World J Gastrointest Oncol 2019; 11(2): 117-138
URL https://www.wjgnet.com/1948-5204/full/v11/i2/117.htm
DOI https://dx.doi.org/10.4251/wjgo.v11.i2.117
Full Article (PDF) WJGO-11-117.pdf
Full Article (Word) WJGO-11-117.docx